The central goal of the Transgenic and Knockout (TKO) Core at the Mayo Clinic Cancer Center is to generate genetically modified mice for MCCC investigators investigating the normal and malignant functions of genes implicated in human cancers. Dr. Jan van Deursen, who has 25 years of experience in generating transgenic and gene-targeted mouse strains, directs the TKO Core. Two experienced technicians. Dr. Wei Zhou and Ms. Ming Li, execute projects on a first-come-first-serve basis. In practicality this means that most projects are initiated within one to two weeks after a request for service. Our main services include: pronuclear microinjection of DNA into fertilized eggs for the production of transgenic mice, transfection of DNA into ES cells for the generation of gene-targeted ES cells or other types of recombinant ES cell clones, injection of ES cell clones into blastocysts for the generation of chimeric mice, sperm cryopreservation, and recovery of cryopreserved mouse strains. These services are all-inclusive allowing investigators with little or no experience in generating transgenics or knockouts to implement genetically altered mice into their research projects. Success rates of all our services are high, with nearly all transgenic projects generating at least 2-3 independent founders and 85-90% of projects involving gene-targeted ES cells or other types of recombinant ES cell clones yielding the desired mutant strains. Service fees of the TKO Core are lower than external users fees for similar services at academic institutions in the US, and much lower than fees of for profit companies. The user base of the TKO Core, which has traditionally been very broad, has expanded dramatically over the current funding period, with 34 MCCC members from eight different programs using the TKO Core. The broadening of the user base is due to implementation of popular new services such as strain cryopreservation and rederivation. 32 of the 34 MCCC members using the TKO Core are extramurally funded. Importantly, a high proportion of successful extramural applications by MCCC members included genetically modified animals generated by the TKO Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-44
Application #
9554054
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications